Duracell inks multiyear partnership with NFL
BETHEL, Conn. — Duracell announced that it has established a multiyear sponsorship with the National Football League.
The sponsorship builds on an agreement that Procter & Gamble has had with the NFL since 2009. Beginning with the 2012 NFL season, Duracell is allowed to use official NFL marks, including Super Bowl XLVII, Pro Bowl, NFL Draft and NFL Playoffs.
Duracell also has furthered the sponsorship — which features the slogan, "Trusted Battery Power of the NFL" — by tapping San Francisco 49ers linebacker Patrick Willis to play a role in the brand’s integrated marketing program, which includes retail, digital, creative, social and event-based initiatives.
"With this sponsorship, we’re reaching millions of passionate and dedicated NFL fans that rely on battery power in their everyday lives," said Volker Kuhn, general manager for Duracell North America. "As an innovator in the category, we can provide peace of mind for consumers and the NFL. Starting this fall, whether it is in a living room or an NFL stadium on Sunday afternoons, Duracell will provide the trusted battery power needed to enjoy or play the game on and off the field."
Global study reveals correlation between insulin dosing irregularities, hypoglycemia
PHILADELPHIA — One-quarter of Type 2 diabetes patients do not take basal insulin as prescribed, while more than one-third suffer from hypoglycemia, according to a global survey funded by Novo Nordisk.
The Global Attitudes of Patients and Physicians survey — which surveyed online 3,042 people with Type 2 diabetes using insulin analog and 1,653 healthcare professionals across six countries — found that in the previous 30 days, 22% of Type 2 diabetes patients worldwide missed a dose of basal insulin, 24% mistimed a dose by more than two hours and 14% reduced a basal insulin dose, while 36% of those surveyed experienced a hypoglycemic event during the same time period.
Researchers also noted a correlation between dosing irregularities and hypoglycemia while conducting the GAPP2 survey. For instance, those who missed a basal insulin dose in the past 30 days were significantly more likely to report self-treated hypoglycemia over the same period (41% compared with 34%).
"A considerable proportion of people with Type 2 diabetes are missing or mistiming their long-acting insulin," said lead researcher and health psychologist Meryl Brod of The Brod Group. "The challenges of addressing dosing irregularities and self-treated hypoglycemia are critical for improving patient care as they greatly impact the achievement of optimal glycemic control."
Genzyme seeks regulatory approval for Lemtrada
CAMBRIDGE, Mass. — A Sanofi company is seeking regulatory approval from the Food and Drug Administration for a drug designed to treat relapsing multiple sclerosis.
Genzyme said it submitted a supplements biologics license application to the FDA for Lemtrada (alemtuzumab), which the drug maker is developing in collaboration with Bayer HealthCare Pharmaceuticals. Genzyme’s clinical development program for the Lemtrada included two phase-3 studies in which results for Lemtrada were superior to Rebif (high dose subcutaneous interferon beta-1a) on clinical and imaging endpoints, including a reduction in relapse rate.
"There remains a large unmet treatment need for patients living with active disease and we believe that Lemtrada, given its efficacy and unique dosing schedule, has the potential to transform the lives of patients with MS," Genzyme president and CEO, David Meeker said.